Eli Lil­ly, UCB and oth­ers Switch in­to gear with $52M for new RNA biotech

South San Fran­cis­co biotech Switch Ther­a­peu­tics un­wrapped Tues­day morn­ing with $52 mil­lion to fi­nance con­di­tion­al­ly ac­ti­vat­ed siR­NA mol­e­cules.

As its name sug­gests, the start­up said it can switch on the mol­e­cules on­ly in se­lect­ed cells so they’re more pre­cise than oth­er RNAi ap­proach­es and can po­ten­tial­ly be ef­fec­tive for longer pe­ri­ods. The biotech will start in the cen­tral ner­vous sys­tem and con­sid­er ex­pand­ing its use in oth­er dis­ease ar­eas through the help of po­ten­tial phar­ma col­lab­o­ra­tors, CEO Dee Dat­ta told End­points News.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN